VIVUS Qysemia REMS barrier to sales, says Brean Capital Brean Capital sees VIVUS' Qyesmia REMS as a significant barrier to sales and sees little evidence to support the company's expectations of a positive FDA decision for REMS modification in April. The firm maintains its Sell rating and $7.00 price target on VIVUS.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital.
Subscribe for More Information
